Rodman & Renshaw Maintains Valeant Pharmaceuticals Intl Inc to Buy with Price Target $105.00

Brokerage firm Rodman & Renshaw Maintains its rating on Valeant Pharmaceuticals Intl Inc(NYSE:VRX). In a research note issued to the investors, the brokerage major Lowers the price-target to $105.00 per share. The shares have been rated Buy. The rating by Rodman & Renshaw was issued on Apr 11, 2016.

In a different note, On Mar 21, 2016, Barclays said it Downgrades its rating on Valeant Pharmaceuticals Intl Inc. In the research note, the firm Lowers the price-target to $135.00 per share. The shares have been rated ‘Equal-weight’ by the firm. On Mar 21, 2016, Mizuho Securities said it Downgrades its rating on Valeant Pharmaceuticals Intl Inc. The shares have been rated ‘Underperform’ by the firm. On Mar 21, 2016, UBS said it Terminates its rating on Valeant Pharmaceuticals Intl Inc. The shares have been rated ‘Buy’ by the firm. On Mar 16, 2016, RBC Capital said it Maintains its rating on Valeant Pharmaceuticals Intl Inc. In the research note, the firm Lowers the price-target to $85.00 per share. The shares have been rated ‘Sector Perform’ by the firm. On Mar 16, 2016, Rodman & Renshaw said it Maintains its rating on Valeant Pharmaceuticals Intl Inc. In the research note, the firm Lowers the price-target to $150.00 per share. The shares have been rated ‘Buy’ by the firm. On Mar 16, 2016, Stifel Nicolaus said it Maintains its rating on Valeant Pharmaceuticals Intl Inc. In the research note, the firm Lowers the price-target to $200.00 per share. The shares have been rated ‘Buy’ by the firm.

Valeant Pharmaceuticals Intl Inc (VRX) shares turned negative on Fridays trading session with the shares closing down -0.22 points or -0.68% at a volume of 2,21,62,520. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $33.138. The peak price level was also seen at $33.138 while the days lowest was $32.01. Finally the shares closed at $32.14. The 52-week high of the shares is $263.81 while the 52-week low is $25.27. According to the latest information available, the market cap of the company is $11,027 M.

Valeant Pharmaceuticals Intl Inc(VRX) last announced its earnings results on Mar 15, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $2.79B. Analysts had an estimated revenue of $2.75B. Earnings per share were $2.50. Analysts had estimated an EPS of $2.61.

Several Insider Transactions has been reported to the SEC. On Nov 9, 2015, J. Michael Pearson (Chief Executive Officer) sold 1,297,399 shares at $78.53 per share price.Also, On Oct 22, 2015, Ronald Harold Farmer (director) purchased 1,500 shares at $175.90 per share price.On Aug 3, 2015, Robert L. Rosiello (CFO) purchased 7,875 shares at $255.62 per share price, according to the Form-4 filing with the securities and exchange commission.

Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products OTC products and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals OTC products and medical device products.

Leave a Reply

Valeant Pharmaceuticals Intl Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Valeant Pharmaceuticals Intl Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.